News

The lead product candidate of Modis Therapeutics is MT1621, an investigational deoxynucleoside substrate enhancement therapy. Currently, MT1621 is in late-stage development for the treatment of Thymidine Kinase 2

The Company is confident it has strong grounds to appeal this decision. The judgment disregards the Company’s compliance with federal and state laws, the unique role its medicines

ADC Therapeutics is currently evaluating ADCT-402 in a pivotal Phase II clinical trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Freenome’s platform will characterize

Otezla is being divested in connection with the ongoing regulatory approval process for the pending merger between Bristol-Myers Squibb and Celgene. The deal may also be valued about

The latest FDA approval is the third for Taltz with the first one coming in 2016 for the treatment of adults with moderate to severe plaque psoriasis. The

Since the original agreement allowing use of POTELLIGENT® Technology was signed in 2015, Cantargia has advanced CAN04 to phase IIa clinical development for potential use in the treatment

The company has reported positive headline results from the pivotal DREAMM-2 open-label and randomised study of two doses of belantamab mafodotin. Belantamab mafodotin is an immuno-conjugate, which included

The deal signed last month by the US-based Gilead Sciences and Galapagos has been cleared under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 by the US Federal Trade

In the Phase 2 portion of the Phase 2/3 study, a multicenter, randomized double-blind trial, all patients received docetaxel 75 mg/m2 on Day 1. Patients were randomly assigned